High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Molecular Biology

Background:

• Medial arterial calcification in chronic kidney disease (CKD) is linked to hyperphosphatemia and is a major cause of cardiovascular mortality.
• The precise mechanisms of high phosphate-induced vascular calcification in CKD remain unclear.

Purpose of the Study:

• To investigate the role of peroxisome proliferator-activated receptor-gamma (PPARγ) in high phosphate-induced vascular calcification in CKD.
• To explore the underlying molecular mechanisms, including the involvement of methyl-CpG binding protein 2 (Mecp2) and Klotho.

Main Methods:

• Analysis of PPARγ expression in arteries from CKD patients and a CKD mouse model.
• In vitro studies using mouse vascular smooth muscle cells (VMSCs) treated with high phosphate.
• Treatment with PPARγ agonist rosiglitazone, Mecp2 manipulation, and Klotho knockdown/deficiency experiments.
• In vivo studies involving oral administration of rosiglitazone in CKD mice.

Main Results:

• High phosphate reduced PPARγ expression in calcified arteries and VMSCs, promoting osteogenic differentiation and calcification.
• Mecp2-mediated epigenetic repression was identified as a mechanism for PPARγ downregulation.
• Klotho expression decreased with PPARγ reduction; rosiglitazone's protective effect was dependent on Klotho.
• Oral rosiglitazone increased Klotho expression and attenuated vascular calcification in CKD mice.

Conclusions:

• PPARγ downregulation, potentially mediated by Mecp2, contributes to high phosphate-induced vascular calcification in CKD.
• The PPARγ-Klotho axis plays a crucial role in this process.
• Targeting PPARγ, possibly through agents like rosiglitazone, represents a potential therapeutic strategy for vascular calcification in CKD.